Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis
about
sameAs
Human cytomegalovirus resistance to antiviral drugsAntiviral drugs for viruses other than human immunodeficiency virusCurrent and potential treatments for ubiquitous but neglected herpesvirus infectionsApproved Antiviral Drugs over the Past 50 YearsComparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovirNonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirusPhenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovirPhosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirusA novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistanceSusceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compoundsInhibition of human cytomegalovirus in culture by alkenyl guanine analogs of the thiazolo[4,5-d]pyrimidine ring systemSynthesis and antiviral activity of 6-benzoyl-benzoxazolin-2-one and 6-benzoyl-benzothiazolin-2-one derivativesHuman cytomegalovirus: challenges, opportunities and new drug developmentDesign, synthesis, and antiviral evaluation of 2-deoxy-D-ribosides of substituted benzimidazoles as potential agents for human cytomegalovirus infectionsUse of human renal proximal tubule cell cultures for studying foscarnet-induced nephrotoxicity in vitroNeoglycolipid conjugates of foscarnet with enhanced antiviral activity in cells infected with human cytomegalovirus and herpes simplex virus type 1Neurotoxicodynamics of the interaction between ciprofloxacin and foscarnet in miceResistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56Antiviral drug resistance of human cytomegalovirus.Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27Resistance of human cytomegalovirus to antiviral drugs.Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers.Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection.Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replicationOcular examination and diagnosis in patients with the acquired immunodeficiency syndrome.Recent strategies in the development of new human cytomegalovirus inhibitors.Prevention and treatment of cytomegalovirus infection in organ transplant recipients.Drug resistance of clinical varicella-zoster virus strains confirmed by recombinant thymidine kinase expression and by targeted resistance mutagenesis of a cloned wild-type isolate.In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDSTreatment of herpesvirus infections in HIV-infected individuals.Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitisPenetration of foscarnet into cerebrospinal fluid of AIDS patients.The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus productionPharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.Detailed polymorphism study on cytomegalovirus DNA polymerase gene to reveal the most suitable genomic targets for quantitative Real-time PCR
P2860
Q24556634-FCB89EFD-8FC8-4B37-AA13-8E8BB34A1579Q24635330-B1EE15C6-B13E-4166-9049-2DE0C2B9B0E2Q27023452-4BA88E93-D0BF-4315-94C2-296A3700DC5FQ27755387-B15F7ED9-4AD6-4FDD-8EF6-36E30C21189DQ28343171-FDE29D8D-8DFF-4CD2-9949-479F9CB9814DQ28343467-A05324DE-9CB0-43B2-AB29-4A373C06E0F8Q28343607-48AFF20E-C3E6-4542-824F-2FCD245E253EQ28345180-B00F28DC-D3EF-4C4D-A793-CBBB7551AFF9Q28348812-EB4002A2-2349-4B0D-B58A-4DEB9FEB09E7Q28365182-31ADD9AD-68C5-412A-93F8-07E5A179C81AQ28367467-E908F3F7-766A-4EB1-A407-F83D703D27BDQ28368061-BCA86045-B68A-49E4-91DA-01298FC75728Q28376487-64F327F8-160A-44EE-9B3E-92494DDF8A4CQ28376935-B8A65544-0BD9-47D9-A0A1-98CE7352A761Q28377197-02763D34-D97F-4ECD-9AA8-4D108F1E9A30Q28378453-C4B4D134-CA6B-4AFF-99F8-26DD0AAEF58FQ28378599-27A2E622-7EA2-42B8-ABD0-346034C5BFB7Q28379415-A2F486C0-133B-4E07-BA37-D61014AFE786Q28379493-93EEE0D0-E3CA-4964-AA51-57D84AC7C561Q30430427-CCD05FD2-4051-428D-BA5A-37C826C90276Q31011523-CC95A9A9-E324-4578-92EB-95496577665AQ33588911-2878E020-48ED-45CD-ADBC-BCEA813D013CQ33815957-14206F85-B1C3-4B9E-85F8-CC0F1367B7B0Q33978415-700BE1EC-0022-44D9-A7DB-1F6CA1FFCF09Q34034462-EA51FDA1-3118-4D0A-8FC5-F2CA9D9C463BQ34102747-EFB64CB2-BAEE-4C94-93CC-2240EA2D01DFQ34111115-5B4E604E-7204-4C24-A169-83C3FAAF32CEQ34210065-093547AC-D87A-4B77-AC29-09835EEE7641Q34218241-FC2D6CE1-36AF-4C3E-B530-53ABC6BBAFEDQ34294851-548DC27D-AF3B-4B48-9ED4-7F3A62F1A05AQ34464333-024C351C-14AA-4236-A9A6-2CE34A7235CAQ35103227-302AF725-6A73-4129-9884-9F31C1769C00Q35118174-821B8DE5-F3EB-4AEE-8ED1-77985AB89C92Q35129803-6B540537-1E83-4967-95B1-04A97AEFB2CCQ35231928-83B6E91A-8FA0-4D34-AB75-B67406AD0C65Q35814373-4A1D9919-94AD-4554-8BF9-6680C5FDFD0EQ35818751-50CE2256-F11B-4F9C-B084-9DB98839CD70Q35847738-AFDE4D1D-DFA8-4230-966B-87F2A64F08DBQ35896783-96298F13-71A1-4781-920F-EEC06358A1F6Q36124353-946B68FF-37D3-4777-A953-4F67C45421D7
P2860
Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis
description
1991 nî lūn-bûn
@nan
1991 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Foscarnet. A review of its ant ...... with cytomegalovirus retinitis
@ast
Foscarnet. A review of its ant ...... with cytomegalovirus retinitis
@en
Foscarnet. A review of its ant ...... with cytomegalovirus retinitis
@nl
type
label
Foscarnet. A review of its ant ...... with cytomegalovirus retinitis
@ast
Foscarnet. A review of its ant ...... with cytomegalovirus retinitis
@en
Foscarnet. A review of its ant ...... with cytomegalovirus retinitis
@nl
altLabel
Foscarnet
@en
Foscarnet
@nl
prefLabel
Foscarnet. A review of its ant ...... with cytomegalovirus retinitis
@ast
Foscarnet. A review of its ant ...... with cytomegalovirus retinitis
@en
Foscarnet. A review of its ant ...... with cytomegalovirus retinitis
@nl
P2093
P921
P1433
P1476
Foscarnet
@en
Foscarnet. A review of its ant ...... with cytomegalovirus retinitis
@en
P2093
Paul Chrisp
S P Clissold
Stephen P. Clissold
P356
10.2165/00003495-199141010-00009
P407
P577
1991-01-01T00:00:00Z
P6179
1049974441